Available in different languages: English, French, Arabic, Russian
Anti-stigma programs have exploded in the United States as well as across
the world in the past decade. Now needed is a more strategic approach to stigma
change, consideration of evaluation strategies that demonstrate its effectiveness.
Q5: For people with dementia, which cognitive/psychosocial interventions (such as cognitive stimulation, cognitive rehabilitation, reality orientation, reminiscence therapy) when compared to placebo/comparator produce benefits/harm in the specified outcomes?
The report “Dementia: a public health priority” has been jointly developed by WHO and Alzheimer's Disease International. The purpose of this report is to raise awareness of dementia as a public health priority, to articulate a public health approach and to advocate for action at international a...nd national levels.
Dementia is a syndrome that affects memory, thinking, behaviour and ability to perform everyday activities. The number of people living with dementia worldwide is currently estimated at 35.6 million. This number will double by 2030 and more than triple by 2050. Dementia is overwhelming not only for the people who have it, but also for their caregivers and families. There is lack of awareness and understanding of dementia in most countries, resulting in stigmatization, barriers to diagnosis and care, and impacting caregivers, families and societies physically, psychologically and economically.
Available Languages: Chinese, English, Japanese, Russian and Spanish
more
Q3: Can febrile seizures (simple or complex) be managed at first or second level care by non-specialist health care providers in low and middle income country settings? What is the role of diagnostic tests in the management of febrile seizures by non-specialists in low and middle income settings? Fo...r prophylaxis to prevent recurrence of simple or complex febrile seizures, which of the pharmacological interventions when compared with placebo/comparator produce benefit/harm in specified outcomes?
- continuous anticonvulsant therapy - intermittent anticonvulsant therapy - intermittent antipyretic treatment
more
Q 7: For adults and children with convulsive epilepsy, which standard antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, valproic acid) when compared to placebo/a comparator produce benefits/harm in the specified outcomes?
Q2: For people with dementia, does memantine, when compared to placebo/comparator, produce benefits/harm in the specified outcomes in non-specialist health settings?
Q3: For behavioural and psychological symptoms in people with dementia, do following drugs, when compared to placebo/comparator, produce benefits/harm in the specified outcomes?
Journal of the ASEAN Federation of Endocrine Societies ; Vol.27 No.1 May 2012 ; Page 34-39
The Equal Rights Review Volume 9, pp.117-137
Q4: Can convulsive epilepsy be diagnosed at first level care by a non-specialist health care provider in low and middle income country settings?
Prevention, early identification, assessment and intervention in low- and middle-income countries | A Review | CHILD AND ADOLESCENT HEALTH AND DEVELOPMENT
Strengthening health-system emergency preparedness.
special education, culture, psychology, education, policy